Welcome to our dedicated page for Mycotopia Therapies news (Ticker: TPIA), a resource for investors and traders seeking the latest updates and insights on Mycotopia Therapies stock.
The TPIA news page provides an archive of announcements and updates related to Mycotopia Therapies Inc. and its transition to operating as AIBiotics. Company communications associated with this symbol trace a path from biopharma and psychedelic-therapy initiatives toward artificial intelligence, robotics and technology-driven wellness products. Readers can use this news history to understand how the business focus evolved and how the corporate identity shifted, including the reported name and symbol change to AIBiotics, Inc. and AIBT.
Earlier news items describe Mycotopia Therapies as a biopharma company focused on research, technology and the development of medical psychedelics, including psychedelic-enhanced psychotherapy and collaborations around naturally derived psilocybin and functional mushrooms. Releases cover supply agreements, strategic investments and planned combinations with partners in the psychedelic and mental wellness sectors, as well as a partnership with PsychedelicsEUROPE to explore opportunities in the European market.
Later articles under the AIBiotics identity highlight the acquisition of AI robotics assets from Philon Labs, centered on the Phill Robot and Milkyway products. These updates detail the development of an AI-powered massage robot and a smart breast milk refrigerator, along with milestones in design, prototyping, patents and crowdfunding. Additional news discusses AIBiotics’ strategy as a developer and manager of AI- and robotics-enhanced companies and technologies, and a letter of intent to acquire DigiTrax Entertainment, a music technology company using AI-based algorithms trained in music theory.
For investors and researchers, this news feed offers context on strategic realignments, proposed and terminated merger plans, product development milestones and corporate actions affecting the TPIA symbol. Reviewing the sequence of releases helps clarify how Mycotopia Therapies repositioned itself as AIBiotics and expanded from psychedelic-focused initiatives into AI, robotics and music technology.
Mycotopia Therapies (TPIA) announced the acquisition of a 12x12 estate in The Sandbox, valuing $2.2M, marking it as the third largest land sale in the Metaverse. This digital land, named PSLY.COM, reflects the synergy between Mycotopia and Ei.Ventures, aiming to blend psychedelic therapy with blockchain technology. Ei.Ventures now owns a total of 144 Sandbox plots. CEO Ben Kaplan cites a booming market, with total sales in The Sandbox reaching $211 million, and anticipates beneficial returns for shareholders from this strategic investment.
Mycotopia Therapies (OTC Pink: TPIA) announced a letter of intent to acquire Ei.Ventures, a pioneer in botanical psilocybin. The acquisition aims to combine resources to develop regulatory-approved therapeutic options and nutritional supplements targeting global mental health needs. The transaction is expected to finalize by Q1 2022, with intentions to rebrand as PSLY.COM. Key products include Psilly, a botanical psilocybin formulation in pre-clinical stages, leveraging the potential 'Entourage Effect' for therapeutic benefits.
Mycotopia Therapies Inc. (TPIA) has initiated a psilocybin-based pharmaceutical program through a 50/50 joint venture with Agile Pharmaceutical Solutions. This partnership aims to develop a sublingual tablet containing psilocybin to potentially treat psychiatric disorders. They seek a Health Canada License to test and market the product. The sublingual method offers rapid absorption and could revolutionize treatments for mental health issues. This venture follows a recent Psilocybin Supply Agreement with Havn Life Sciences for natural psilocybin.
Mycotopia Therapies (TPIA) announced key advancements in its strategic plan, establishing itself as a biopharma company focused on psychedelic-derived medicines. The company secured DTC eligibility for enhanced liquidity, signed a supply agreement with Havn Life Sciences for naturally-derived psilocybin, and signed letters of intent for partnerships to develop water-soluble psychedelics. Plans include opening psilocybin and ketamine clinics in Jamaica, addressing mental health crises. The company aims to recruit a top-tier board to lead its mission of revolutionizing mental health treatment.
Mycotopia Therapies (OTC Pink: TPIA) has entered a Psilocybin Supply Agreement with Havn Life Sciences to facilitate the export of naturally-derived psilocybin from Canada to the U.S. This partnership aims to establish a distribution channel for psychedelic therapies to universities and researchers, positioning Mycotopia to be among the first to market as demand for psychedelic substances increases. The global psychedelics market is projected to grow from $2.077B in 2019 to $6.859B by 2027. CEO Ben Kaplan emphasized that this agreement accelerates their path to revenue generation.
Mycotopia Therapies (TPIA) announced the acquisition of PsyTech Inc. by Wesana Health for approximately $21 million CAD in Wesana stock. The acquisition includes Tovana Solutions and Tovana Clinics, which will rebrand as Wesana Clinics, expanding from two to an estimated twelve clinics within a year. Additionally, PsyTech Connect offers a large community of over 8,000 professionals in psychedelic therapy. Wesana aims to leverage these resources to enhance patient care and therapy protocols. The deal requires shareholder approval and is expected to close in Q3 2021.
Mycotopia Therapies (OTC Pink: TPIA) announced a virtual Psychedelic Industry Summit on July 19-20, 2021. This complimentary event aims to connect investors and interested individuals with industry experts. The summit features panels discussing ketamine-assisted therapy and microdosing, with notable speakers like Rick Doblin and Matthew W. Johnson. Participants can register for free general admission or premium access for $97. Mycotopia holds a 10% interest in PsychedeliTech, the parent company of PsyTech, which is leading innovation in psychedelic therapies.
Mycotopia Therapies Inc. (OTC Pink: TPIA) has completed its name and symbol change, trading under its new stock symbol from May 4, 2021. This move aligns with the company's transition into psychedelic therapies, targeting conditions like anxiety, depression, and PTSD through technology-focused solutions. Additionally, the company is working towards securing DTC eligibility for the electronic settlement of its common shares in the U.S. Learn more at Mycotopia Therapies Inc..